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Prediction of Clinical Outcomes in Primary Biliary
Cirrhosis by Serum Enhanced Liver Fibrosis Assay
Marlyn J. Mayo,1,22 Julie Parkes,2 Beverley Adams-Huet,3 Burton Combes,4,22 A. S. Mills,5 Rodney S. Markin,6
Raphael Rubin,7 Donald Wheeler,8 Melissa Contos,5 A. B. West,9 Sandra Saldana,10 Yonas Getachew,11 Robert Butsch,3
Velimir Luketic,12 Marion Peters,13 Adrian Di Bisceglie,14 Nathan Bass,14 John Lake,15 Thomas Boyer,16
Enrique Martinez,17 James Boyer,18 Guadalupe Garcia-Tsao,19 David Barnes,20 and William M. Rosenberg21
Primary biliary cirrhosis (PBC) is sometimes diagnosed based on a positive antimitochondrial
antibody in the appropriate clinical setting without a liver biopsy. Although a liver biopsy can
assess the extent of liver fibrosis and provide prognostic information, serum fibrosis markers
avoid biopsy complications and sampling error and provide results as a continuous variable,
which may be more precise than categorical histological stages. The current study was under-
taken to evaluate serum fibrosis markers as predictors of clinical progression in a large cohort of
PBCpatients. Serial liver biopsy specimens and serumsampleswere collected every2 years in161
PBC subjects for a median of 7.3 years. Clinical progression was defined as development of one
or more of the following events: varices, variceal bleed, ascites, encephalopathy, liver transplan-
tation, or liver-related death. Serumhyaluronic acid, tissue inhibitor ofmetalloproteinase 1, and
procollagen III aminopeptideweremeasured and entered into the previously validated enhanced
liver fibrosis (ELF) algorithm. The ability of ELF, histological fibrosis, bilirubin, Model for
End-StageLiverDisease (MELD), andMayoRisk Score to differentiate between individualswho
would experience a clinical event from those who would not was evaluated at different time
points. Event-free survival was significantly lower in those with high baseline ELF. Each 1-point
increase in ELF was associated with a threefold increase in future complications. The prognostic
performance of all tests was similar when performed close to the time of the first event.However,
at earlier times in the disease process (4 and 6 years before the first event), the prognostic
performance of ELF was significantly better thanMELD orMayo R score.Conclusion:The ELF
algorithm is a highly accurate noninvasive measure of PBC disease severity that provides useful
long-term prognostic information. (HEPATOLOGY 2008;48:1549-1557.)
Abbreviations: AUROC, area under the receiver operating characteristic curve; CI, confidence interval; ELF, enhanced liver fibrosis; MELD,Model for End-Stage Liver
Disease; PBC, primary biliary cirrhosis; ROC, receiver operating characteristic.
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Some patients with primary biliary cirrhosis (PBC)will have a normal life span without complications,whereas others will progress to complications of cir-
rhosis, liver failure, and death.1 Accurately predicting
clinical outcomes in patients with PBC presents a chal-
lenge. Surrogate markers of disease progression are
needed for multiple reasons, including providing prog-
nostic information to patients, optimizing referral time
for liver transplantation, and serving as endpoints in clin-
ical trials.2 The Model for End-Stage Liver Disease
(MELD) and Mayo Prognostic Model for PBC (Mayo R
score) are prognostic models that have been validated in
PBC patients as predictors of death. They are widely used
to determine appropriate timing of liver transplantation,
but these models were not originally developed to detect
disease progression at earlier stages of PBC. Liver biopsy
has been the only reliable means to assess prognosis in all
stages of disease. However, the accuracy of liver biopsy is
limited by sampling error, subjective interpretations, lim-
ited frequency of biopsies, and categorical staging sys-
tems. Noninvasive surrogate markers are appealing
because they do not pose the same risks of pain and bleed-
ing as liver biopsy; they can be performed frequently and
provide a score that is a continuous variable, potentially
capable of tracking progression from mild fibrosis
through to end-stage cirrhosis. Serum fibrosis markers
could potentially replace liver biopsy as the test of choice
for determining the position of a patient along the spec-
trum of disease severity. However, their prognostic accu-
racy compared with liver biopsy has not been assessed in
PBC.
The correlation between serum fibrosis markers and
histology in other chronic liver disease is good but not
perfect. Thus, clinicians have been reluctant to substitute
serum fibrosis markers for histological staging. Most
marker panels show similar ability to distinguish signifi-
cant from insignificant fibrosis in cross-sectional studies,
with area under the receiver operating characteristic curve
(AUROC) of approximately 0.8.3-5 However, imperfect
correlation attributable to biopsy sampling error is to be
expected, and only longitudinal studies with clinical end-
points can determine the prognostic accuracy of biochem-
ical markers of disease severity. Very few studies have
acquired sufficient follow-up data to evaluate clinical out-
comes. Amongst 357 patients with alcoholic liver disease,
those with elevated serum YKL-40 (growth factor) or N-
terminal propeptide of type III procollagen had shorter
survival than patients with normal serum levels of
YKL-40 or N-terminal propeptide of type III procolla-
gen.6 In a group of 537 treated and untreated patients
with hepatitis C, fibrosis biomarkers had a similar but
statistically better ability than biopsy to predict hepatitis-
related complications over a 5-year period.7 This study
investigated the hypothesis that serum fibrosis markers
would predict clinical progression as well as or better than
current methods of disease staging in primary biliary cir-
rhosis. This is the first study to evaluate serum fibrosis
markers in a large cohort of patients with primary biliary
cirrhosis patients and in particular to examine the ability
of serum fibrosis markers to predict clinical outcomes.
Patients and Methods
Patients. One hundred sixty-one patients with PBC
were prospectively followed between 1993 and 2003 as
part of a multicenter U.S. clinical trial (Primary Biliary
Cirrhosis Ursodiol Methotrexate Placebo Study
[PUMPS]) that was designed to investigate whether low-
dose weekly methotrexate, when added to ursodiol, im-
proved survival or delayed progression of PBC.
Methotrexate was not found to affect the course of PBC,8
so patients from both treatment arms were combined for
the purpose of the current analysis. Combining treatment
arms was also later justified by a subanalysis demonstrat-
ing no effect of the treatment arm on the outcomes of this
analysis. Only patients with established but not decom-
pensated PBC were enrolled into the parent trial. Partic-
ipants were required to have both a positive anti-
mitochondrial antibody and either an abnormal alkaline
phosphatase or at least stage 1 disease on liver biopsy.
Exclusion criteria included a history of variceal bleeding,
ascites, or encephalopathy.
Investigations. Subjects received a history, physical
examination, and serum blood tests at entry and every 3
months. At entry and at 2-year intervals, they also under-
went percutaneous liver needle core biopsy to assess his-
tological changes, endoscopy to look for new varices, and
abdominal ultrasound to look for new ascites. On the
same day as these procedures, serum for long-term storage
was obtained, frozen, and later used for the serum fibrosis
marker assay. Thus, all biochemical, serological, and his-
tological data were precisely synchronized. Biopsy speci-
mens were coded with a unique subject identifier and
date. They were fixed and stained with hematoxylin-eosin
for assessment of cell morphology and trichrome stain for
assessment of fibrosis. Each biannual biopsy was read by
four independent pathologists and a mean PBC stage of 1
to 4 (explained in Table 1) was calculated. Pathologists
convened on an annual basis to independently read those
biopsy specimens that had been collected over the preced-
ing 12 months. Biopsy specimens were read in isolation;
that is, pathologists did not confer, and previous biopsy
specimens from the same subject were not compared with
newly acquired biopsy specimens. Each pathologist read
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each biopsy only once, except for a single pathologist (S.
Mills), who, at the request of the National Institutes of
Health, also read each biopsy using the Ishak scoring sys-
tem to quantify fibrosis (Table 1).9 Routine laboratories
[bilirubin, albumin, international normalized ratio
(INR), creatinine] were performed at each center
throughout the trial. Model for end-stage liver disease
(MELD) and Mayo R scores were calculated as described
previously. Enhanced liver fibrosis (ELF) test scores, were
determined on frozen sera after the close of the study. The
ELF assay, which includes serum hyaluronic acid, tissue
inhibitor of metalloproteinase 1, and N-terminal propep-
tide of type III procollagen, was previously developed and
validated as a predictor of histological fibrosis in a cohort
of 1921 patients with chronic liver disease, including 53
patients with either PBC or primary sclerosing cholangi-
tis.3 All assays are heterogeneous immunoassays employ-
ing amagnetic particle separation technique developed by
Bayer Diagnostics and now property of Siemens Molecu-
lar Solutions.3
Analysis. Each of the potential prognostic tests (ELF,
histology, serum bilirubin, Mayo R score, and MELD)
was then examined for its ability to separate patients who
developed clinical progression from those who did not.
Clinical progression was defined as the development of
one of the following events: new varices, variceal bleed,
ascites, encephalopathy, liver-related death, or liver trans-
plantation.
Two types of analyses were performed to examine the
predictive ability of the prognostic tests. In the forward-
looking analysis, the ability of each baseline test result
(ELF, Ishak score, PBC stage, bilirubin, MELD, Mayo R
score) to predict development of a clinical event during
follow-up was analyzed. Each of the baseline test scores
were divided into three subgroups (low, intermediate, and
high score), and the frequency of progression in each sub-
group was determined. A Kaplan-Meier time-to-event
curve was generated for each subgroup. A Cox propor-
tional hazard ratio was modeled, using ELF and the mean
histological PBC stage of the four pathologists as contin-
uous variables.
A rear-looking analysis was also performed to address
the possibility that some tests might be better long-range
predictors in patients with earlier disease. The rear-look-
ing analysis was designed to account for heterogeneity of
disease severity in the study population at the time of
entry into the parent trial. This analysis looked retrospec-
tively at tests performed at 0, 2, 4, 6, or 8 years before the
development of the first clinical event. For example, in
subjects who developed new varices, the data measured at
the time of the endoscopy are designated “0 years prior” to
the event. In subjects who never developed a clinical
event, data were used from the last date the individual was
known to be completely free of complications. At each of
these time points, the ability of each test to predict
whether the subject would later develop a clinical event
was determined. Receiver operator curve (ROC) curves
were generated to compare the diagnostic performance of
each of the tests at each time point in the disease process.
The AUROCs for each test were compared using a non-
parametric approach,10 including both omnibus and pair-
wise comparisons. To adjust for multiple comparisons, a
P-value of0.01 was considered significant for the pair-
wise testing.
ELF scores were correlated with biopsy findings using
the Spearman rank order correlation test. An ROC curve
Table 2. Characteristics of Study Population at Study Entry
(n  161)
Characteristic No Event (n  119) Event (n  42) P-Value
Age 51.1  8.8 53.0  8.4 0.24
ELF 0.17  0.72
0.14
1.10  0.98
1.14
0.0001
Ishak score (0-6) 2.37  1.34
2.0
3.14  1.18
3.0
0.0008
PBC stage (1-4) 1.98  0.70
1.0
2.50  0.87
1.75
0.0009
Bilirubin 0.54  0.28
0.50
0.81  0.53
0.60
0.002
MELD 6.30  0.66
6.0
7.02  1.55
6.0
0.001
Mayo risk 3.68  0.64
3.66
4.15  0.60
4.21
0.0001
Results are expressed as mean  standard deviation and median.
Table 1. Fibrosis Scoring Systems
Ishak Score Characteristic
0 No fibrosis
1 Fibrous expansion of some portal areas, with or without
short septae
2 Fibrous expansion of most portal areas, with or without
short septae
3 Fibrous expansion of most portal areas with occasional
portal to portal (P-P) and/or portal to central (P-C)
bridging
4 Fibrous expansion of portal areas with marked bridging
(P-P as well as P-C)
5 Marked bridging (P-P as well as P-C) with occasional
nodules (incomplete cirrhosis)
6 Cirrhosis (probable or definite)
PBC Stage Characteristic
1 No fibrosis. (There had to be some portal inflammation
on the initial biopsy to be enrolled)
2 Non- bridging fibrosis. (Portal tracts expanded beyond
the limiting plate with any degree of fibrosis less
than stage 3.)
3 Bridging fibrosis (Two or more portal-portal bridges)
4 Cirrhosis (at least one regenerative nodule surrounded
by fibrosis)
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was generated to examine the ability of ELF score to pre-
dict histological fibrosis. Serial assessments of ELF that
were made over the 8-year follow-up duration were eval-
uated for change over time by estimating the slopes of the
regression line from initial to final ELF determination
with random coefficient models. Comparisons of the
slopes between the event and no-event groups were made
with linear contrasts from the random coefficient model.
Themodeling and fitting was performed in SAS 9.1. (SAS
Institute, Cary, NC) using the PROC MIXED proce-
dure.
Results
Themedian follow-up of the 161 subjects was 7.3 years
(range, 5 months to 10 years). Most subjects were white
(93%) and female (93%). During follow-up, 42 (26%) of
the subjects developed one of the events defined as clinical
progression: onset of varices (n 33), variceal bleed (n
0), ascites (n 6), encephalopathy (n 1), liver-related
death (n 1), or liver transplantation (n 1). Although
most of these subjects had the onset of varices as their first
event, this was often followed by one or more of the other
events.
The characteristics of the study population are shown
in Table 2. The mean scores of all prognostic tests were
significantly higher at study entry in the group that pro-
gressed to develop clinical events during follow-up.
Adequacy of Liver Biopsy Specimens. Of the 578
liver biopsy specimens used in this study, the median
biopsy length was 1.7 cm (minimum, 1 cm; maximum, 5
cm). Most biopsy specimens (80%) had six portal tracts
per tissue core. Fewer than 1% had more than six portal
tracts per biopsy. Very few (7%) had fewer than four
portal tracts, and the remainder (13%) had four or five
portal tracts per biopsy. The biopsy specimens were frag-
mented in 47% of cases. Pathologists were given the op-
tion to interpret a biopsy as “inadequate for staging,”
which occurred in one instance. The weighted kappa
score for interpathologist variability in assessing PBC
stage was 0.62.
Forward-Looking Event-Free Survival. The chance
of developing a clinical event was examined in persons
with either low, intermediate, or high scores on each of
the prognostic tests obtained at baseline. There was a
significant correlation between the baseline score of all
prognostic tests and the likelihood of developing a clinical
complication over the next 6 years (Table 3). Only 8% of
subjects with a low baseline ELF score developed a com-
plication during follow-up, whereas 24% of subjects with
an intermediate score and 46% of subjects with high a
score developed a clinical complication. In a Cox’s pro-
portional hazard model adjusting for age and treatment
arm (the latter had no effect), each increase in ELF score
by 1 point was associated with a threefold increase in
future complications (relative risk, 2.9; 95%CI, 2.0-4.3).
Every stage increase of PBC stage (1-4 point scale) led to
a twofold increase in future complication rate [relative
risk, 2.4; 95% confidence interval (CI), 1.6-3.6].
Fig. 1. Event-free survival by baseline ELF score. Kaplan-Meier curve
of time to first clinical event by ELF score. Low ELF: 1.32 to 0.08;
Intermediate ELF: 0.06 to 0.669; High ELF: 0.67-3.23. Event –free
survival was significantly lower in patients with higher baseline ELF
scores.
Table 3. Clinical Progression According to Baseline
Prognostic Test
Test Subgroup
Subgroup
Value
Clinical Event*
Yes No
ELF† Low -1.32 to -0.08 4 (8%) 49 (92%)
Intermediate -0.06 to 0.669 13 (24%) 41 (76%)
High 0.67 to 3.23 25 (46%) 29 (54%)
Ishak score Low 0-1 1 (4%) 25 (96%)
Intermediate 2-3 25 (25%) 74 (75%)
High 4-6 16 (46%) 19 (54%)
PBC stage Low 2.0 12 (17%) 57 (83%)
Intermediate 2.0-2.9 12 (20%) 47 (80%)
High 3-4 18 (55%) 15 (45%)
Bilirubin Low 1.0 32 (22%) 114 (78%)
Intermediate 1.1-2.0 8 (62%) 5 (38%)
High 2.0 2 (100%) 0 (0%)
MELD Low 6.0 24 (20%) 95 (80%)
Intermediate 7-10 17 (41%) 24 (59%)
High 11 1 (100%) 0
Mayo risk Low 3.5 8 (14%) 48 (86%)
Intermediate 3.5-3.9 9 (21%) 34 (79%)
High 4.0 25 (40%) 37 (60%)
*P  0.004 for all prognostic tests, event group versus no event group,
comparison by Cochran-Armitage Trend test.
†ELF is categorized by tertiles.
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ELF performed as well as either Ishak score or PBC
stage.
The event-free survival according to baseline ELF score
is depicted in Fig. 1. The log rank test comparing the
three subgroups showed a highly significant difference
(P  0.0001) in event-free survival depending on the
baseline ELF score.
Rear-Looking Prediction of Clinical Progression.
The ability of each test to predict whether a subject
would later develop a clinical event was also retrospec-
tively determined at increasing time intervals (0, 2, 4,
6, and 8 years) before the first event. For each time
point, ROC curves were generated for each diagnostic
test (Fig. 2), and the AUROC was calculated (Table 4)
as a measure of the prognostic value of each test. The
AUROCs of the various tests were not significantly
different from each other at years 0 and 2 (anaysis of
variance, P  0.24 at 0 years and P  0.25 at 2 years).
However, at earlier time points in the disease process (4
and 6 years before the first complication), there were
significant differences (analysis of variance P  0.003
at 4 years and P 0.007 at 6 years). The differences in
the prognostic tests performed 8 years before the first
clinical event were also significant (P  0.001); how-
ever, the confidence interval of the AUROCs were
quite wide at this time because of the small number of
patients in the event group at that time, which made
comparisons between tests difficult to interpret.
Fig. 2. Performance of prognostic tests at specified time points in the disease process of PBC. The ability of each prognostic test to predict whether
an individual would develop a clinical complication was examined at different time points before the first event. Near the time of the first event (year
0), the ROC curves overlapped considerably. However, at earlier times (4 and 6 years before the first clinical event), ELF score and histological fibrosis
performed better as prognostic tests. (analysis of variance P  0.003 at 4 years and P  0.007 at 6 years).
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At each time point in the disease process, Ishak staging
system and ELF score had highest predictive values (AU-
ROC). In fact, there was no statistically significant differ-
ence in the AUROC of ELF and histological staging at
any time point. The AUROC of histological staging by
the seven-point Ishak system was consistently slightly
greater than the AUROC of the four-point PBC stage.
The prognostic performance of ELF (AUROC) was also
higher than the other noninvasive tests (bilirubin,
MELD,Mayo risk score) at each time point, although this
difference was not statistically significant at later points in
the disease process (0 and 2 years before the first event).
The most strongly significant differences were between
ELF andMayo R score AUROCs at earlier time points in
the disease process (4 and 6 years before the first event;
P  0.004 and P  0.009, respectively).
Correlation of ELF with Histology. The initial ELF
score in each subject correlated well with the extent of
disease on liver biopsy, using either the Ishak scoring sys-
tem (rho 0.52, P 0.0001) or the PBC staging system
(rho  0.60, P  0.0001) However, as expected, there
wasmuch overlap in individual ELF scores, particularly in
persons with intermediate stages of histological fibrosis
(Fig. 3). ELF score was an accurate noninvasive marker of
histological fibrosis. The AUROC of ELF to predict cir-
rhosis (Ishak 5-6) score was 0.76 (95%CI 0.63-0.89) and
to predict significant fibrosis (Ishak 3-6) was 0.75 (CI
0.67-0.82) (Fig. 4)
Serial Determinations of ELF. One hundred forty-
nine subjects hadmore than one frozen serum sample and
thus could be used to evaluate change in serial ELF score
determinations over the 8-year follow-up period. The
ELF score increased by 0.032 per year (95% CI: 0.008-
0.005, P 0.009), and the rate of increase was no differ-
ent comparing the event (slope 0.046 per year, CI:
0.002 to 0.094, n 38) and no event (slope 0.027 per
year, 95%CI: 0 to 0.054, n 111) groups (P  0.50).
Discussion
This is the first study to examine the utility of a serum
fibrosis marker panel in primary biliary cirrhosis, and in
particular, to predict clinical outcomes. The relationship
between the baseline ELF score and the likelihood of de-
veloping a clinical complication over the next 6 years was
highly significant, as demonstrated by the event-free sur-
vival Kaplan-Meier analysis.
Other noninvasive prognostic models, such as the
Mayo R score and MELD, are based on bilirubin, albu-
min, prothrombin time, edema, and creatinine. These
biochemical and clinical markers become abnormal in the
later stages of cirrhosis and hepatic dysfunction, which is
why they are excellent predictors of death.However, these
markers are not sensitive to disease progression earlier in
the course of PBC. This is most likely the explanation for
the poor prognostic performance of Mayo R score,
MELD, and bilirubin 6 years before the first clinical
event, similar to the chance of flipping a coin (AUROC
0.420-0.564). Even though the parent trial was not orig-
inally designed to compare prognostic tests, the availabil-
ity of concurrent data and long-term follow-up enabled us
to make comparisons and determine retrospectively the
most accurate prognostic tests.
Clinical jaundice is known to be a late but poor prog-
nostic sign in PBC. The PUMPS trial excluded patients
with a history of bilirubin greater than 2.0, so only two
patients in this cohort had jaundice at study entry. Al-
though both of these patients did develop a clinical event,
a large percentage of patients with normal baseline biliru-
bin also progressed to have a clinical event. In the retro-
Table 4. Performance of Prognostic Tests in PBC: Area Under the Receiver Operating Characteristic Curves with 95%
Confidence Intervals
Test
Area Under ROC (CI)
Years Prior to First Complication
0 2 4 6 8
European Liver Fibrosis Panel 0.748
(0.651-0.845)
0.739
(0.653-0.825)
0.682
(0.578-0.786)
0.684
(0.528-0.841)
0.784
(0.600-0.968)
Ishak score
(0-6)
0.732
(0.627-0.836)
0.743
(0.647-0.839)
0.721
(0.617-0.824)
0.751
(0.606-0.896)
0.584
(0.423-0.745)
PBC stage
(1-4)
0.706
(0.583-0.829)
0.675
(0.562-0.788)
0.634
(0.505-0.764)
0.657
(0.471-0.843)
0.305
(0.077-0.534)
Bilirubin
(loge)
0.650
(0.526-0.774)
0.659
(0.541-0.777)
0.617
(0.501-0.732)
0539
(0.368-0.711)
0.559
(0.098-1.0)
MELD 0.642
(0.538-0.746)
0.630
(0.531-0.729)
0.544
(0.439-0.649)
0.592
(0.455-0.730)
0.612
(0.327-0.898)
Mayo PBC
risk score
0.680
(0.564-0.796)
0.625
(0.518-0.733)
0.501
(0.388-0.614)
0.431
(0.294-0.568)
0.441
(0.119-0.763)
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spective analysis, taking the loge of bilirubin improved its
prognostic ability, although the AUROC of loge bilirubin
(reported in this paper) was still lower than that of ELF or
histology.
The key components of the ELF algorithm are hyal-
uronic acid, tissue inhibitor of metalloproteinase 1, and
procollagen type III N-terminal propeptide, which are
expressed during early stages of collagen deposition in the
liver, and this is most likely the reason that ELF retains its
prognostic ability even in early stages of the disease pro-
cess (AUROC, 0.737-0.863 at all time points). None of
the prognostic tests, however, including biopsy and ELF,
had AUROCs of over 0.9. Thus, no test is error-free when
trying to predict clinical progression, and this must be
considered when counseling individual patients in the
clinical setting.
Liver biopsy has been the reference standard for staging
PBC and other chronic liver diseases for over 50 years, and
the prognostic information gained from liver biopsy is
useful. The three most popular staging systems for PBC
are the Ludwig, Popper, and Scheuer systems.11-13 This
study used the the Ludwig system, which has become
favored over the others because it is increasingly recog-
nized that florid duct lesions or ductular proliferation
need not be present to define early stages. ELF algorithm
was found to be superior to PBC stage at all time points
for predicting clinical progression. Of course, a liver bi-
opsy provides additional diagnostic information, but this
is not always necessary. A typical middle-aged woman
with cholestatic liver tests, positive AMA, and no other
liver disease risk factors does not require a confirmatory
liver biopsy.14 Although not originally developed for
PBC, the Ishak system was also used to score each of the
biopsy specimens in this study. The performance of the
Ishak score was not statistically different from the perfor-
mance of the ELF score. Thus, we propose that if a liver
biopsy is not needed for diagnostic purposes, the ELF
score can be used for prognostic staging and monitoring
during follow-up. In the situation in which a liver biopsy
is appropriate for diagnostic purposes, the Ishak system
should be used for more accurate staging. The Ishak sys-
tem is based entirely on the extent of fibrosis and provides
better prognostic information but cannot establish the
diagnosis of PBC. The diagnosis must still be made by the
presence of typical histological features such as nonsup-
purative destructive cholangitis.
The possibility of replacing staging liver biopsies with
simple noninvasive marker algorithms is gaining momen-
tum as evidence is accumulating in other chronic liver
diseases that these panels are reasonable surrogate markers
of histological liver fibrosis. Several cross-sectional studies
Fig. 3. Distribution of first ELF score according to biopsy score. The
first serum ELF score correlated well with histology. Because the mean
PBC stage was derived by averaging the scores of four pathologists, the
calculated values ranged from 1.0 to 4.0, in increments of 0.25.
Fig. 4. ELF as a predictor of histological fibrosis and cirrhosis. ELF
score was an accurate noninvasive marker of histological fibrosis. The
AUROC of ELF to predict cirrhosis was 0.76 (95% CI 0.63-0.89) and to
predict significant fibrosis was 0.75 (CI 0.67-0.82)
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have evaluated the ability of marker panels to quantify
fibrosis in hepatitis C and nonalcoholic fatty liver dis-
ease.15-19 Consistently, these marker panels are reasonably
accurate at distinguishing the absence of fibrosis from
advanced cirrhosis, but the accuracy of the test in a single
individual, particularly an individual with an intermedi-
ate degree of fibrosis, is lower.15,20-23 These studies have
been criticized because the “gold standard” of histology is
inaccurate because of the high rate of sampling error
known to occur in patients with diffuse parenchymal liver
diseases.24 One study of patients with cirrhosis from dif-
ferent causes demonstrated that three samples taken by
the same route in the same patients were concordant for
the degree of fibrosis in only 50% of cases.25 Although
increasing the length of the biopsy improves diagnostic
accuracy, the rate of discordance in biopsy specimens
larger than 25 mm is still 25% in hepatitis C.26 Thus,
although “bigger is better,” needle biopsies are by their
nature somewhat inaccurate. PBC, in particular, is char-
acterized by patchy involvement of portal areas. Whole
section scanning of 50 PBC liver explants demonstrated
that only 20% of PBC livers have a consistent histological
stage of fibrosis throughout the liver, even when the tissue
was obtained at clinically defined end-stage disease.27 The
correlation between ELF score and histological fibrosis in
these patients was strong. However, as expected, there was
also significant overlap of individual ELF scores, particu-
larly in persons with intermediate stages of histological
fibrosis. The ELF score, therefore, was not a perfect re-
flection of the histological fibrosis score; however, its ex-
cellent performance as a prognostic marker implies that
biopsy error may actually account for part of the discord
between ELF and histological fibrosis score.
One advantage of the current study was that serial se-
rum samples were available in a very well-defined cohort
with meticulously determined clinical outcomes over a
long period. Thus, prognostic tests could be evaluated at
different time points and also evaluated for change over
time. The average ELF score increased over time (by
0.032 per year). This average rate of increase was not
different between subjects who experienced an event and
those who did not, which indicates that the rate of PBC
fibrosis progression may be relatively steady, regardless of
whether the starting point is early or advanced disease. It
also suggests that the patients who developed the clinical
events started the study at a later time point in their dis-
ease process. These data argue against the theory that
there may be a rapidly fibrotic and slowly fibrotic form of
PBC, at least in the cohort studied here.
In conclusion, the ELF algorithm is a highly accurate
noninvasivemeasure of PBC disease severity that provides
accurate prognostic information. The ability of this algo-
rithm to predict clinical outcomes is as good as or better
than traditional prognostic tests for PBC, particularly in
early stages of the disease. It is a simple, noninvasive tech-
nique with long-range predictive ability that should be
very useful in the clinical assessment of PBC.
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